Date: May 12, 2025
Attention: Prescribers
Effective date: May 6, 2025
Call to action: Due to the shortage, Health and Human services Commission (HHSC) removed the non-preferred status of the drugs in the table below from the authorized generic (AG) fluticasone HFA products on the preferred drug list (PDL), effective May 6, 2025.
Background: The manufacturers of brand-name Asmanex HFA, Organon, and QVAR RediHaler, Teva
Pharmaceuticals, reported product backorders due to distribution and manufacturing delays.
How this impacts providers: These changes allow providers to prescribe the AG fluticasone HFA products without requiring a PDL prior authorization and continue access to necessary asthma control medications for members.
| NDC | Drug Name |
| 66993-0078-96 | FLUTICASONE PROP HFA 44 MCG |
| 66993-0079-96 | FLUTICASONE PROP HFA 110 MCG |
| 66993-0080-96 | FLUTICASONE PROP HFA 220 MCG |
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
If you have any questions, please email Provider Relations at tchppharmacy@texaschildrens.org.
For access to all provider alerts: www.texaschildrenshealthplan.org/provideralerts.